1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature \> 104.0 degrees f, pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications, found in appendix ii 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine 8. inability to attend daily for 10 days

1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature \> 104.0 degrees f, pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications, found in appendix ii 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine 8. inability to attend daily for 10 days

refusal to sign informed consent form negative test for covid-19 by rt-pcr at screening severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 104.0 degrees f, pleuritic pain, or frequent cough. known drug allergy to any of the investigational medications currently taking medication with known drug interactions with investigational medications, found in appendix ii prescription or other antiviral medications any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine inability to attend daily for 10 days

refusal to sign informed consent form negative test for covid-19 by rt-pcr at screening severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 104.0 degrees f, pleuritic pain, or frequent cough. known drug allergy to any of the investigational medications currently taking medication with known drug interactions with investigational medications, found in appendix ii prescription or other antiviral medications any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine inability to attend daily for 10 days

1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 104.0 degrees f, pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications, found in appendix ii 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine 8. inability to attend daily for 10 days

1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 104.0 degrees f, pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications, found in appendix ii 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine 8. inability to attend daily for 10 days

1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnoea, shortness of breath, temperature > 38 degrees c (100.4 degrees f), pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications, found in appendix ii 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine 8. inability to attend daily for 10 days

1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnoea, shortness of breath, temperature > 38 degrees c (100.4 degrees f), pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications, found in appendix ii 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine 8. inability to attend daily for 10 days